ArticleJournal of diabetes investigation2020
Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus.
Article in Journal of diabetes investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Relationship of asprosin and diabetes: a meta-analysis.BMC endocrine disorders · 2025Pooled it
- Pooled it
- Circulating Asprosin Concentrations and Body Weight Changes in Postmenopausal Women: Findings from the Women's Health Initiative.The Journal of nutrition · 2026Article
- YY1/Asprosin/PFKP axis regulates glycolytic metabolic and exacerbates pathological cardiac hypertrophy.Nature communications · 2026Article
- Beyond glycemia: adropin, asprosin, and irisin as potential biomarkers for cardiovascular risk in diabetes and prediabetes.Scientific reports · 2026Article
- Effect of submaximal and maximal training on serum levels of asprosin, metabolic parameters and body composition in overweight and obese women.Journal of diabetes and metabolic disorders · 2025Article
- Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- The correlation between serum asprosin and type 2 diabetic patients with obesity in the community.Frontiers in endocrinology · 2025Article
- The Associations between Asprosine, Clusterin, Zinc Alpha-2-Glycoprotein, Nuclear Factor Kappa B, and Peroxisome Proliferator-Activated Receptor Gamma in the Development of Complications in Type 2 Diabetes Mellitus.Journal of clinical medicine · 2024Article
- Asprosin: its function as a novel endocrine factor in metabolic-related diseases.Journal of endocrinological investigation · 2024Review
- Association of serum asprosin with metabolic dysfunction-associated fatty liver disease in older adult type 2 diabetic patients: a cross-sectional study.BMC endocrine disorders · 2024Article
- Asprosin is positively associated with metabolic syndrome in hemodialysis patients: a cross-sectional study.Renal failure · 2023Article
- Whole-Body Cryotherapy Improves Asprosin Secretion and Insulin Sensitivity in Postmenopausal Women-Perspectives in the Management of Type 2 Diabetes.Biomolecules · 2023Article
- Article
- Molecular cloning, characterization and 3D modelling of spotted snakehead fbn1 C-terminal region encoding asprosin and expression analysis of fbn1.Scientific reports · 2023Article
- Asprosin Enhances Cytokine Production by a Co-Culture of Fully Differentiated Mature Adipocytes and Macrophages Leading to the Exacerbation of the Condition Typical of Obesity-Related Inflammation.International journal of molecular sciences · 2023Article
- Correlation of asprosin and Nrg-4 with type 2 diabetes Mellitus Complicated with Coronary Heart Disease and the Diagnostic Value.BMC endocrine disorders · 2023Article
- Asprosin promotes feeding through SK channel-dependent activation of AgRP neurons.Science advances · 2023Article
- Association of cord blood asprosin concentration with atherogenic lipid profile and anthropometric indices.Diabetology & metabolic syndrome · 2022Article
- Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by theMolecular syndromology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionAsprosin is a novel secreted adipokine that is induced by fasting and promotes hepatic glucose release. In healthy humans, circulating asprosin shows circadian oscillation with an acute drop coinciding with the onset of eating. The present study investigated whether this circadian oscillation still exists in patients with type 2 diabetes mellitus. MATERIALS AND
methodsWe recruited 60 patients with type 2 diabetes mellitus and 60 individuals with normal glucose tolerance (NGT). All participants completed a 75-g oral glucose tolerance test. Fasting and 2-h postprandial serum asprosin concentrations were measured by the enzyme-linked immunosorbent assay method. Partial correlation coefficients were calculated to analyze the relationships between serum asprosin level and parameters of glucose metabolism. Multiple logistic regression analysis was used to determine the association of serum asprosin level with diabetes.
resultsBoth fasting and postprandial asprosin levels were significantly higher in patients with type 2 diabetes mellitus. The postprandial asprosin level was apparently lower than fasting asprosin level in individuals with NGT. The fasting asprosin level closely correlated with type 2 diabetes mellitus after multiple adjustment (odds ratio 2.329, P = 0.023). Asprosin correlated negatively with change in blood glucose (r = -0.502, P < 0.001) and change in C-peptide (r = -0.467, P < 0.001) in individuals with NGT, but not in type 2 diabetes mellitus patients.
conclusionsSerum asprosin level decreased coinciding with the onset of the oral glucose tolerance test in individuals with NGT, whereas this circadian oscillation was disturbed in type 2 diabetes mellitus patients. The impaired response of asprosin to glucose fluctuation in type 2 diabetes mellitus patients might be one of the reasons for the onset of type 2 diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.